Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder |
| |
Affiliation: | 1. Butler Hospital, Providence, RI, USA;2. Brown University, Department of Psychiatry and Human Behavior, Providence, RI, USA;3. Sheppard Pratt Health System, Baltimore, MD, USA;4. Department of Psychiatry, University of Maryland, Baltimore, MD, USA;5. Southern California TMS Center, Los Angeles, CA, USA;6. Neuronetics Inc., Malvern, PA, USA;7. TMS of South Tampa, Tampa, USA;8. FL USA University, Augusta, GA, USA;9. NAMSA, St. Louis Park, MN, USA;10. Nashville NeuroCare Therapy, Nashville, TN, USA;11. Department of Psychiatry, Columbia University, NY, USA;12. Department of Radiology, Columbia University, NY, USA |
| |
Abstract: | BackgroundTranscranial magnetic stimulation (TMS) is an effective treatment for major depressive disorder (MDD). The rest time between pulse trains is the inter-train interval (ITI). Since 2016, some TMS clinicians have adopted a stimulation protocol with shorter ITIs than were used in regulatory clinical trials.ObjectiveTo contrast treatment outcomes with the Standard TMS protocol (38.5 min per session) and the “Dash” protocol, which, at the shortest ITI, has a session duration of 18.75 min.MethodsRegistry data were collected at 103 practice sites. Of 7759 participants, 5010 were included in an intent-to-treat (ITT) sample, defined as a primary MDD diagnosis, age ≥ 18, and completion of the PHQ-9 before TMS and with at least one PHQ-9 assessment after baseline. Completers (N = 3814) were responders or had received ≥ 20 sessions and had an end of acute treatment PHQ-9 assessment. Within the ITT sample, 613 patients were treated with the Standard NeuroStar 38-min protocol and 1493 patients with the new Dash protocol. CGI-S ratings were obtained in smaller samples. Treatment outcomes were also examined in subgroups considered Completers, as well as the subgroups who met criteria for Full Adherence to the Standard or Dash protocol parameters.ResultsIn the ITT, Completer, and Fully Adherent samples, response (58–72%) and remission (28–53%) rates were notably high across PHQ-9 and CGI-S ratings. The Standard and Dash protocols did not differ in number of treatment sessions, and both manifested strong antidepressant effects.ConclusionsThe Standard and Dash protocols did not meaningfully differ in efficacy. |
| |
Keywords: | CGI-S" },{" #name" :" keyword" ," $" :{" id" :" kwrd0015" }," $$" :[{" #name" :" text" ," _" :" Clinical Global Impression – Severity scale DLPFC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0025" }," $$" :[{" #name" :" text" ," _" :" dorsolateral prefrontal cortex ITT" },{" #name" :" keyword" ," $" :{" id" :" kwrd0035" }," $$" :[{" #name" :" text" ," _" :" intention-to-treat MDD" },{" #name" :" keyword" ," $" :{" id" :" kwrd0045" }," $$" :[{" #name" :" text" ," _" :" major depressive disorder MT" },{" #name" :" keyword" ," $" :{" id" :" kwrd0055" }," $$" :[{" #name" :" text" ," _" :" motor threshold PHQ-9" },{" #name" :" keyword" ," $" :{" id" :" kwrd0065" }," $$" :[{" #name" :" text" ," _" :" Patient Health Questionnaire-9 TMS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0075" }," $$" :[{" #name" :" text" ," _" :" transcranial magnetic stimulation |
本文献已被 ScienceDirect 等数据库收录! |
|